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Case Presentation
In March 2002, a 27-year-old man presented
with sudden loss of central vision in the right
eye. Visual loss in the left eye followed
within 18 days. At the time of onset, the
patient was a very light occasional drinker
and a moderate smoker (15 cigarettes/day for
5 years; unfortunately, cotinine and trans-3´-
hydroxycotinine were not measured to assess
tobacco smoke exposure). He suffered from
chronic headaches, which responded to com-
mon painkillers. The headaches had report-
edly worsened when he started work in a glue
factory in 1998 (he had previously been an
electrician) and worsened remarkably when
he was transferred to the glue preparation
department, where he had worked for
6 months before the loss of vision. At fundus
examination, both eyes showed micro-
angiopathy and pseudoedema of the optic
disc. A cycle of corticosteroids was ineffective
at this time. One month later, visual acuity
was 1/100 in the right eye and 7/10 in the left
eye. We observed the patient in June 2002
and found a bilateral paleness of optic discs
and the inability to count ﬁngers with either
eye; at that time, the patient complained of
disturbing photopsias. A therapy with
idebenone (270 mg/day) and brimonidine
(2 drops, 3 times/day) was initiated (Mashima
et al. 2000; Newman et al. 2005). Mitochon-
drial (mt) DNA testing on a blood sample was
positive for homoplasmic 11778G → A/ND4
mutation. Haplogroup deﬁnition showed that
this patient’s mtDNA belonged to haplo-
group H (DdeI 10394-, AluI 7025-, MseI
14766-) (Torroni et al. 1997). These ﬁndings
are consistent with a diagnosis of Leber heredi-
tary optic neuropathy (LHON), a maternally
inherited loss of central vision that preferen-
tially affects young men (Man et al. 2002);
three mtDNA point mutations (positions
11778G → A/ND4, 3460G → A/ND1, and
14484T → C/ND6) are found in over 90% of
patients worldwide.
Until January 2003, visual function pro-
gressively deteriorated, reaching almost com-
plete loss of vision (apart from hand motion)
with rapid, involuntary eyeball oscillation
(nystagmus). Progression of the ﬁber loss was
documented by serial optical coherence
tomography (Barboni et al. 2005). Figure 1
shows the retinal nerve fiber layer (RNFL)
thickness in each quadrant, as measured by
optical coherence tomography, for each of the
patient’s eyes after 9, 10, and 15 months,
alongside values for historical groups of
healthy subjects and of patients in an
advanced stage of LHON (with atrophy of the
optic nerve) (Barboni et al. 2005). Compared
with the control group, both of the patient’s
eyes at 9, 10, and 15 months follow-up
showed a progressively thinner RNFL in all
quadrants.
By January 2003 (10 month follow-up),
the patient needed assistance to walk. After
June 2003, he reported a slow but progressive
improvement. A full clinical reevaluation was
performed in September 2005; abnormal
findings were limited to poor visual acuity,
pale optic discs, and sluggish pupillary light
reaction. On a standardized cycloergometer test
(Montagna et al. 1995), serum lactic acid levels
were almost normal (11.5, 11.9, 23.0, and
13.0 mg/dL; normal range, 5.8–22.0 mg/dL).
Folate and vitamin B12 were normal, whereas
creatine phosphokinase was high (289 U/L;
normal value, < 170 U/L). Muscle biopsy
showed nonspeciﬁc changes, with an observable
parcellar subsarcolemmal increase of succinic
dehydrogenase staining, indicating some mito-
chondrial proliferation. The patient is now able
to count fingers and is without nystagmus
(both eyes). He is able to walk without assis-
tance and is continuing the same treatment. 
Maternal lineage reconstruction. Because
the mutations associated with LHON affect
complex I subunits and, in most families, are
homoplasmic (100% of mtDNA copies are
mutant), we performed genealogical recon-
struction for the maternal lineage of the
patient’s family. After obtaining informed
consent, we collected blood from the patient’s
siblings and mother for mtDNA testing by
restriction fragment length polymorphism
analysis, as described by Torroni et al. (1997).
These subjects were unaffected carriers of the
homoplasmic 11778/ND4 LHON mutation.
No history of occupational or environmental
exposure to solvents (or other particular toxic
substances) was reported for any of the family
members tested (Figure 2). These results are
in accordance with the current concepts
regarding LHON; the mtDNA mutation is a
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CONTEXT: Leber hereditary optic neuropathy (LHON) is a maternally inherited loss of central vision
related to pathogenic mutations in the mitochondrial genome, which are a necessary but not sufﬁ-
cient condition to develop the disease. Investigation of precipitating environmental/occupational
(and additional genetic) factors could be relevant for prevention.
CASE PRESENTATION: After a 6-month period of occupational exposure to n-hexane and other
organic solvents, a 27-year-old man (a moderate smoker) developed an optic neuropathy. The
patient had a full ophthalmologic and neurologic investigation, including standardized cyclo-
ergometer test for serum lactic acid levels and a skeletal muscle biopsy. His exposure history was also
detailed, and he underwent genetic testing for LHON mitochondrial DNA mutations. The patient
suffered a sequential optic neuropathy with the hallmarks of LHON and tested positive for the
homoplasmic 11778G → A/ND4 mutation. Routine laboratory monitoring revealed increased con-
centrations of urinary 2.5 hexandione (n-hexane metabolite) and hippuric acid (toluene metabolite)
in the period immediately preceding the visual loss.
DISCUSSION: In a subject carrying an LHON mutation, the strict temporal sequence of prolonged
appreciable occupational exposure followed by sudden onset of visual loss must raise a suspicion of
causality (with a possible further interaction with tobacco smoke). 
RELEVANCE: In this article, we add to the candidate occupational/environmental triggers of LHON
and highlight the need for appropriate case–control (and laboratory) studies to validate the causal
effect of mixed toxic exposures.
KEY WORDS: environmental trigger, Leber hereditary optic neuropathy, mitochondrial DNA,
neurotoxin, n-hexane, occupational exposure, solvents. Environ Health Perspect 115:113–115
(2007). doi:10.1289/ehp.9245 available via http://dx.doi.org/ [Online 19 September 2006]
Research | Environmental Medicinenecessary but not sufficient condition for
LHON, and only a minority of carriers devel-
ops optic neuropathy. Penetrance is incom-
plete (and lower in women), implying that
additional mitochondrial/nuclear genetic fac-
tors and possibly also environmental factors
contribute to phenotypic expression of
LHON (Carelli et al. 2003); however, these
triggering factors are poorly deﬁned.
Occupational exposure history. Between
1998 and 2000 the patient had worked in the
“hot-melt” department, where he controlled
hot layering of a synthetic adhesive contain-
ing styrene-isoprene copolymer, isopropilic
alcohol, toluene, xylene, and octanes. An
environmental exposure assessment requested
by factory inspectors in 2003 indicated vapor
levels of the individual solvents were 10–20%
of American Conference of Governmental
Industrial Hygienists (ACGIH) threshold
limit values (TLVs) (ACGIH 2005). During
1998–2000, the patient recalled experiencing
nausea, dizziness, asthenia, and paresthesia of
the upper and lower limbs (in addition to
chronic headaches) whenever he had to clean
the machines—a task he performed using a
mixture of styrene, isopropilic alcohol,
toluene, xylene, and octanes. In 2000–2001
the patient worked in the rubber-mincing
department, where he was indirectly exposed
to n-hexane and toluene (no quantitative data
are available). In the glues preparation depart-
ment, where the patient worked from
October 2001 to March 2002, exposure to
n-hexane and toluene was presumably more
direct because of the nature of his duties: He
prepared coloring mixtures containing rub-
ber, hydrocarbonic resin of toluene, and
n-hexane in a closed production cycle, and he
opened dissolver machines 5 times/day to
determine if the tanks were empty. The only
available environmental monitoring data for
the department (again requested post hoc in
2003) report peak values of 10.7 mg/m3 for
n-hexane (ACGIH TLV, 176 mg/m3) and
1.5 mg/m3 for toluene (ACGIH TLV,
188 mg/m3). In this department, the patient
reported constantly feeling nauseous and
dizzy. Also, during the 6-month period, four
overflow accidents occurred, each reportedly
followed by several hours of intensiﬁed dizzi-
ness and nausea, asthenia, tingling of the
upper and lower limbs, and dysesthesia of the
hands (the same set of symptoms the patient
recalled experiencing after using solvents for
cleaning tasks in the hot-melt department).
Biological monitoring data routinely collected
throughout the period of employment indi-
cated that after the patient moved to the glue
preparation department, he had a > 4-fold
increase in urinary 2,5-hexandione (a neuro-
toxic metabolite of n-hexane) from 0.5–0.9 to
4.1 mg/L, accompanied by a > 1.5-fold
increase in urinary hippuric acid (a toluene
metabolite) from 360–700 to 1,040 mg/L
(roughly corresponding to an increase from
0.26–0.5 to 0.74 g/g creatinine).
Discussion
In a subject without speciﬁc genetic predisposi-
tion, the appreciable biological exposure levels
of urinary 2,5-hexandione (4.1 mg/L) and
hippuric acid (1,040 mg/L, roughly equivalent
to 0.74 g/g creatinine) encountered in the glue
factory would not elicit concern for major
neurologic involvement [although the biologi-
cal exposure indices adopted by the ACGIH
are 0.4 mg/L for 2,5-hexandione and 1.6 g/g
creatinine for hippuric acid (ACGIH 2005)].
The observed association could have been
casual because the patient was a smoker and
the presentation of LHON was rather typical.
Nevertheless, in a subject carrying an LHON
mutation, the strict temporal sequence of a
prolonged appreciable occupational exposure
followed by sudden onset of visual loss must
raise a suspicion of causality. 
At present, no speciﬁc evidence is available
for any association between solvents and
LHON. Johns et al. (1992) reported an iso-
lated case of an LHON patient with occupa-
tional exposure to solvent fumes—a ﬁreﬁghter
repeatedly exposed to xylene, toluene, and
methylethylketone, as well as smoke and other
fumes. It is reasonable to suppose that both in
the case of this ﬁreﬁghter and in our patient, it
may have been an acute exposure to solvents
that triggered the onset of LHON. Recently, a
late-onset LHON case was reported to follow
a long history of occupational exposure to
polycyclic aromatic hydrocarbons (Rufa et al.
2005). Putative associations have been sug-
gested between solvents and other optical/
retinal neuropathies (Maruff et al. 1998;
Meadows and Verghese 1996). In a report on
15 workers exposed to n-hexane in an adhesive
bandage factory, 11 workers showed macular
changes and 1 had central retinopathy (Raitta
et al. 1978). Several case reports describe optic
neuropathy and/or hearing loss among glue
sniffers (Ehyai and Fremon 1983; Ogawa
et al. 1988; Williams 1988). Furthermore,
peripheral neuropathy and sensorineural hear-
ing loss was described in a painter exposed to a
mixture of organic solvents, including toluene
and xylene (Moshe et al. 2002). Occupational
exposure to (or snifﬁng of) toluene is thought
to have an acute effect on color vision that is
capable of inducing retinal and optic nerve
degeneration (Gobba and Cavalleri 2003;
Kiyokawa et al. 1999). Interestingly, in vitro
data suggest that the neurotoxic effects of
styrene are related to mitochondrial damage,
in addition to oxidative stress (Darè et al.
2004). Regarding isopropanol, experiments on
rats showed that inhalation of this alcohol
boosts renal and hepatic microsomial metabo-
lism of n-hexane, leading to increased forma-
tion of neurotoxic metabolites (Zahlsen et al.
1984). Animal studies on n-hexane exposure
also indicate that 2,5-hexanedione [the known
neurotoxic n-hexane metabolite (Spencer and
Schaumburg 1985)] could provoke premature
or accelerated deterioration in vision (Spencer
and Schaumburg 1978) and, by reducing the
rate of ATP synthesis, decrease the endoge-
nous concentration of ATP in brain mito-
chondria (Sickles et al. 1990). Moreover,
n-hexane uncouples mitochondrial respiration
by a nonprotonophoric mechanism (Canton
et al. 1996). The uncoupling effect and
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Figure 1. RNFL thickness in each quadrant of the eye, as measured by optical coherence tomography.
(A) Right eye. (B) Left eye. Solid lines refer to the patient’s eyes at 9, 10, or 15 months of follow-up; dashed
and dotted lines refer to historical groups of healthy subjects (control) and of patients in an advanced stage
of LHON with atrophy of the optic nerve (Barboni et al. 2005).
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Figure 2. Three-generation reconstruction of the
patient’s maternal line. mtDNA analysis of the
patient and his mother and siblings (asterisks)
revealed the homoplasmic 11778/ND4 LHON muta-
tion in all four of them; however, the patient was
the only family member affected.
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Patientimpaired ATP synthesis induced by n-hexane
(or its neurotoxic metabolite) suggest that this
compound could be a candidate trigger for
LHON in our patient. Although n-hexane
and toluene toxicity is not thought to be
severe at our patient’s exposure level, the pos-
sible neurotoxic potentiation of the mixed
exposure has to be considered (Noraberg and
Arlien-Soborg 2000). Solvents, their metabo-
lites, and tobacco smoke derivatives (the
patient was a moderate smoker) could interact
with the biochemical defect related to the
LHON mutation on complex I (Carelli et al.
2004). Although it is not possible to draw
conclusions about any triggering role of
n-hexane, toluene, and/or other solvents and
smoking exposures, it is noteworthy that the
patient did suffer other signs and symptoms
suggestive of toxic exposure before the onset
of LHON. 
Many aspects of the complex etiology of
LHON remain poorly defined (Man et al.
2002; Carelli et al. 2004). The incomplete
penetrance and the male propensity clearly
indicate that the mtDNA mutation is not the
only determinant for disease expression.
Research is required into secondary factors
modulating the clinical expression of
LHON, which could include toxic expo-
sures, alcohol/tobacco abuse, and metabolic
dysfunctions (Lachmund and Mojon 2006).
One case–control study failed to reveal asso-
ciations with smoking and/or alcohol drink-
ing (Kerrison et al. 2000), whereas another
reported associations with smoking and aspe-
cific occupational toxic exposures (Sadun
et al. 2003). Nevertheless, individuals
exposed to substances with neurotoxic prop-
erties (including ethanol and smoke) affect-
ing hepatic or renal function or solvent
metabolism generally tend to be particularly
vulnerable to exposure to organic solvents
(Spencer and Schaumburg 1985). 
Conclusion
Epidemiologic and biological studies are
needed to explore secondary factors modulat-
ing the clinical expression of LHON, includ-
ing metabolic, lifestyle, environmental, and
occupational triggers. Possible differential
effects of chronic and acute exposures to sol-
vents and other toxic substances require 
consideration. 
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